Sex Hormone-Binding Globulin

Biomarker

Related News

Progress in Nonhormonal Male Contraception Advances in Early Clinical Studies

May 11, 2026

Early clinical studies highlighted nonhormonal male contraception candidates YCT-529 and ADAM. YCT-529 showed favorable phase 1a safety, while ADAM reported mild transient effects and durability up to 24 months.

Evidence on ketogenic diets remains mixed across mental health, diabetes, and PCOS

Apr 21, 2026

Evidence on ketogenic diets remains limited for psychiatric disorders and diabetes, while a systematic review in overweight and obese women with PCOS found significant short-term improvements. Experts said more controlled, long-term studies are needed.